<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Hls Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/hls-therapeutics-inc</link>
<description>Latest news and press releases for Hls Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/hls-therapeutics-inc" rel="self" type="application/rss+xml" />
<item>
<title>HLS Therapeutics to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-to-present-at-the-2026-bloom-burton-and-co-healthcare-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-to-present-at-the-2026-bloom-burton-and-co-healthcare-investor-conference</guid>
<pubDate>Tue, 14 Apr 2026 11:00:00 GMT</pubDate>
<description>HLS Therapeutics to Present at the 2026 Bloom Burton &amp; Co. Healthcare Investor Conference ...</description>
</item>
<item>
<title>HLS Therapeutics Announces Fiscal 2025 Financial Results</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-fiscal-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-fiscal-2025-financial-results</guid>
<pubDate>Thu, 12 Mar 2026 10:30:00 GMT</pubDate>
<description>HLS Therapeutics Announces Fiscal 2025 Financial Results Canada NewsWire Adjuste...</description>
</item>
<item>
<title>HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-nilemdotm-bempedoic-acid-is-now-available-in-canada-for-the-reduction-of-ldl-cholesterol-in-patients-at-risk-of-cardiovascular-disease</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-nilemdotm-bempedoic-acid-is-now-available-in-canada-for-the-reduction-of-ldl-cholesterol-in-patients-at-risk-of-cardiovascular-disease</guid>
<pubDate>Thu, 05 Mar 2026 12:00:00 GMT</pubDate>
<description>HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reductio...</description>
</item>
<item>
<title>HLS Therapeutics to Host Fiscal 2025 Financial Results Conference Call</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-to-host-fiscal-2025-financial-results-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-to-host-fiscal-2025-financial-results-conference-call</guid>
<pubDate>Thu, 26 Feb 2026 12:00:00 GMT</pubDate>
<description>HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release financial results for the three and twelve months ended December 31, 2025, on Thursday, March 12, 2026. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Craig Millian, Chief Executive Officer; John Hanna, Chief Financial Officer; and Brian Walsh, Chief Commercial Officer. Slides to accompany management's prepared remarks will be availab</description>
</item>
<item>
<title>Esperion Partner HLS Therapeutics Announces Approval of NILEMDO&#xAE; for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/esperion-partner-hls-therapeutics-announces-approval-of-nilemdoandxae-for-the-reduction-of-ldl-cholesterol-in-canadians-at-risk-of-cardiovascular-disease</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/esperion-partner-hls-therapeutics-announces-approval-of-nilemdoandxae-for-the-reduction-of-ldl-cholesterol-in-canadians-at-risk-of-cardiovascular-disease</guid>
<pubDate>Tue, 18 Nov 2025 12:00:00 GMT</pubDate>
<description>ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that ...</description>
</item>
<item>
<title>HLS Therapeutics Announces Health Canada Approval of NILEMDO&#xAE; for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-health-canada-approval-of-nilemdoandxae-for-the-reduction-of-ldl-cholesterol-in-canadians-at-risk-of-cardiovascular-disease</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-health-canada-approval-of-nilemdoandxae-for-the-reduction-of-ldl-cholesterol-in-canadians-at-risk-of-cardiovascular-disease</guid>
<pubDate>Tue, 18 Nov 2025 12:00:00 GMT</pubDate>
<description>HLS Therapeutics Announces Health Canada Approval of NILEMDO&#xAE; for the Reduction of LDL-Chole...</description>
</item>
<item>
<title>HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-health-canada-120000263</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-health-canada-120000263</guid>
<pubDate>Tue, 18 Nov 2025 12:00:00 GMT</pubDate>
<description>HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Health Canada has approved NILEMDO® (bempedoic acid) for use in Canada and has issued a Notice of Non-Compliance ("NON") for NEXLIZET® (bempedoic acid and ezetimibe). HLS in-licensed the exclusive rights to NILEMDO and NEXLIZET for the Canadian market from Esperion Therapeutics Inc. ("Esperion")</description>
</item>
<item>
<title>HLS Therapeutics Announces Q3 2025 Financial Results</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-q3-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-q3-2025-financial-results</guid>
<pubDate>Thu, 13 Nov 2025 11:30:00 GMT</pubDate>
<description>HLS Therapeutics Announces Q3 2025 Financial Results Canada NewsWire Adjusted EB...</description>
</item>
<item>
<title>HLS Therapeutics to Host Q3 2025 Financial Results Conference Call</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-to-host-q3-2025-financial-results-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-to-host-q3-2025-financial-results-conference-call</guid>
<pubDate>Thu, 30 Oct 2025 11:00:00 GMT</pubDate>
<description>HLS Therapeutics to Host Q3 2025 Financial Results Conference Call Canada NewsWire ...</description>
</item>
<item>
<title>HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT&#xAE; and EPA Mechanistic Data at the Canadian Cardiovascular Congress</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-and-amarin-collaborate-on-presenting-reduce-itandxae-and-epa-mechanistic-data-at-the-canadian-cardiovascular-congress</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-and-amarin-collaborate-on-presenting-reduce-itandxae-and-epa-mechanistic-data-at-the-canadian-cardiovascular-congress</guid>
<pubDate>Tue, 14 Oct 2025 12:43:00 GMT</pubDate>
<description>HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT&#xAE; and EPA Mechanistic Data at...</description>
</item>
<item>
<title>HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-amarin-collaborate-presenting-124300020</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-amarin-collaborate-presenting-124300020</guid>
<pubDate>Tue, 14 Oct 2025 12:43:00 GMT</pubDate>
<description>HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, in collaboration with its partner, Amarin Corporation plc (NASDAQ: AMRN) announce the presentation of scientific data at the upcoming Canadian Cardiovascular Congress ("CCC") in Quebec City, from October 23 to 26, 2025. These presentations reflect the continued commitment of HLS and Amarin to advancing the bro</description>
</item>
<item>
<title>HLS Therapeutics Announces New Credit Agreement</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-new-credit-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-new-credit-agreement</guid>
<pubDate>Wed, 20 Aug 2025 12:30:00 GMT</pubDate>
<description>HLS Therapeutics Announces New Credit Agreement Canada NewsWire CAD $79...</description>
</item>
<item>
<title>HLS Therapeutics Announces Q2 2025 Financial Results</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-q2-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-q2-2025-financial-results</guid>
<pubDate>Thu, 14 Aug 2025 10:31:00 GMT</pubDate>
<description>HLS Therapeutics Announces Q2 2025 Financial Results Canada NewsWire Adju...</description>
</item>
<item>
<title>HLS Therapeutics to Host Q2 2025 Financial Results Conference Call</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-to-host-q2-2025-financial-results-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-to-host-q2-2025-financial-results-conference-call</guid>
<pubDate>Thu, 31 Jul 2025 11:00:00 GMT</pubDate>
<description>HLS Therapeutics to Host Q2 2025 Financial Results Conference Call Canada NewsWire ...</description>
</item>
<item>
<title>HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Plan</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-reimbursement-vascepa-103000922</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-reimbursement-vascepa-103000922</guid>
<pubDate>Wed, 02 Jul 2025 10:30:00 GMT</pubDate>
<description>HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into a Product Listing Agreement ("PLA") with the province of Nova Scotia, for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with Nova Scotia Pharmacare is effective July 1, 2025.</description>
</item>
<item>
<title>HLS Therapeutics Announces Reimbursement for Vascepa&#xAE; under Nova Scotia's Provincial Drug Plan</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-reimbursement-for-vascepaandxae-under-nova-scotias-provincial-drug-plan</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-reimbursement-for-vascepaandxae-under-nova-scotias-provincial-drug-plan</guid>
<pubDate>Wed, 02 Jul 2025 10:30:00 GMT</pubDate>
<description>HLS Therapeutics Announces Reimbursement for Vascepa&#xAE; under Nova Scotia's Provincial Drug Pl...</description>
</item>
<item>
<title>HLS Therapeutics Reports Annual Meeting Results</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-reports-annual-meeting-results</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-reports-annual-meeting-results</guid>
<pubDate>Fri, 20 Jun 2025 20:30:00 GMT</pubDate>
<description>HLS Therapeutics Reports Annual Meeting Results Canada NewsWire TORONTO ...</description>
</item>
<item>
<title>HLS Therapeutics Announces Q1 2025 Financial Results</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-q1-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-announces-q1-2025-financial-results</guid>
<pubDate>Thu, 08 May 2025 10:32:00 GMT</pubDate>
<description>HLS Therapeutics Announces Q1 2025 Financial Results Canada NewsWire Tota...</description>
</item>
<item>
<title>HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL&#xAE; and NEXLIZET&#xAE; in Canada</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-partners-with-esperion-therapeutics-to-commercialize-nexletolandxae-and-nexlizetandxae-in-canada</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-partners-with-esperion-therapeutics-to-commercialize-nexletolandxae-and-nexlizetandxae-in-canada</guid>
<pubDate>Thu, 08 May 2025 10:30:00 GMT</pubDate>
<description>HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL&#xAE; and NEXLIZET...</description>
</item>
<item>
<title>HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada</title>
<link>https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-partners-esperion-therapeutics-103000823</link>
<guid isPermaLink="true">https://6ix.com/company/hls-therapeutics-inc/news/hls-therapeutics-partners-esperion-therapeutics-103000823</guid>
<pubDate>Thu, 08 May 2025 10:30:00 GMT</pubDate>
<description>HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into an agreement with Esperion Therapeutics Inc. ("Esperion") (NASDAQ: ESPR) to in-license and commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada. All financial figures are in U.S. dollars unless otherwise stated.</description>
</item>
</channel>
</rss>